BC Week In Review | Mar 24, 1997
Clinical News

Watson regulatory update

WATS's Oclassen Pharmaceuticals Inc. subsidiary (San Rafael, Calif.) received FDA marketing approval for Condylox Gel 0.5 percent (podofilox) to treat external genital and perianal warts. The product is expected to be launched in the second...
BC Week In Review | Sep 11, 1995
Company News

Oclassen Pharmaceuticals Inc., Healthpoint Medical deal

Oclassen licensed its Iodosorb and Iodoflex (cadexomer iodine) wound cleansing agents to Healthpoint (San Antonio). Oclassen (San Rafael, Calif.) said it licensed the products to concentrate on its core business in dermatology, which includes Condylox...
BC Week In Review | Jan 16, 1995
Company News

Oclassen Pharmaceuticals Inc. deal

Bock Pharmacal Co.'s 240-person sales force will handle all promotional activities for Oclassen’s Condylox (podofilox) genital wart solution to obstetricians, gynecologists, primary care physicians and public health clinics. Oclassen (San Rafael, Calif.) will continue to...
BC Week In Review | Jan 10, 1994
Company News

Oclassen Pharmaceuticals Inc. deal

Oclassen (San Rafael, Calif.) licensed U.S. marketing rights for Iodosorb Gel (cadexomer iodine) from Perstorp Pharma (Sweden). The gel, sold in England and Japan, disinfects wounds while absorbing fluid exudates, Oclassen said. Oclassen also received...
Items per page:
1 - 4 of 4